Benu BioVentures, a subsidiary of Benu BioPharma, creates and finances virtual biopharmaceutical companies to de-risk validated candidate drugs. The experienced development team at Benu works with founders to demonstrate human safety and proof of concept in a cost and time efficient program. We seek to create a data package that will be the basis for a license/partnership with a larger company, who will be responsible for completing clinical development and marketing developed drugs. Benu is not positioned to invest in discovery or creation of new platforms.

Press Release

BOSTON, MA, September 11, 2013 Benu BioVentures to Focus on Moving Pharmaceutical Candidates to Human Proof-of-Concept Benu BioPharma announced today the establishment of Benu BioVentures, a new biopharmaceutical investment initiative to fund and develop preclinical stage pharmaceutical investments to the human proof-of-concept stage. Leveraging Benu BioPharma’s management expertise in technology commercialization and pharmaceutical development, Benu BioVentures is creating and financing virtual companies that will move candidate drugs toward human proof of concept studies in a cost and time efficient manner. Funding activities will focus on product candidates with strong animal data and a clear regulatory path that address unmet medical needs. Benu BioVentures is led by Dennis Goldberg, Ph.D., FAHA and Fred Meyer, Ph.D., CFA, both recognized biopharmaceutical serial entrepreneurs. According to Dennis Goldberg, Co-Founder and Partner, “With our clinical, regulatory and corporate development capabilities, we can offer founders a unique solution to the current funding gap for product focused start-ups. We collaborate with founders to move their drug candidates into the clinic and then partner with a large pharma or biotech company to complete development.”